PL2766397T3 - Ulepszone składanie przeciwciał bispecyficznych - Google Patents
Ulepszone składanie przeciwciał bispecyficznychInfo
- Publication number
- PL2766397T3 PL2766397T3 PL12778018T PL12778018T PL2766397T3 PL 2766397 T3 PL2766397 T3 PL 2766397T3 PL 12778018 T PL12778018 T PL 12778018T PL 12778018 T PL12778018 T PL 12778018T PL 2766397 T3 PL2766397 T3 PL 2766397T3
- Authority
- PL
- Poland
- Prior art keywords
- bispecific antibodies
- improved assembly
- assembly
- improved
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545863P | 2011-10-11 | 2011-10-11 | |
| US201161546503P | 2011-10-12 | 2011-10-12 | |
| US201161560704P | 2011-11-16 | 2011-11-16 | |
| US201261676837P | 2012-07-27 | 2012-07-27 | |
| EP12778018.7A EP2766397B1 (en) | 2011-10-11 | 2012-10-11 | Improved assembly of bispecific antibodies |
| PCT/US2012/059810 WO2013055958A1 (en) | 2011-10-11 | 2012-10-11 | Improved assembly of bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2766397T3 true PL2766397T3 (pl) | 2018-10-31 |
Family
ID=47073551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18167907.7T PL3418306T3 (pl) | 2011-10-11 | 2012-10-11 | Ulepszone składanie przeciwciał dwuswoistych |
| PL12778018T PL2766397T3 (pl) | 2011-10-11 | 2012-10-11 | Ulepszone składanie przeciwciał bispecyficznych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18167907.7T PL3418306T3 (pl) | 2011-10-11 | 2012-10-11 | Ulepszone składanie przeciwciał dwuswoistych |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9862778B2 (pl) |
| EP (2) | EP3418306B1 (pl) |
| JP (1) | JP6216321B2 (pl) |
| KR (3) | KR102492792B1 (pl) |
| CN (2) | CN104093744A (pl) |
| BR (1) | BR112014008684B1 (pl) |
| CA (1) | CA2850818A1 (pl) |
| ES (2) | ES2682081T3 (pl) |
| HK (1) | HK1202878A1 (pl) |
| HR (2) | HRP20240230T1 (pl) |
| HU (1) | HUE065876T2 (pl) |
| MX (1) | MX359384B (pl) |
| PL (2) | PL3418306T3 (pl) |
| RU (1) | RU2654567C2 (pl) |
| SI (1) | SI2766397T1 (pl) |
| TR (1) | TR201809151T4 (pl) |
| WO (1) | WO2013055958A1 (pl) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0711282B2 (ja) | 1990-02-23 | 1995-02-08 | シーケーデイ株式会社 | ロツドレスシリンダ |
| JPH07111203B2 (ja) | 1991-09-06 | 1995-11-29 | エスエムシー株式会社 | ロッドレスシリンダ |
| DE4137789C2 (de) | 1991-11-16 | 1994-01-20 | Festo Kg | Linearantrieb |
| SI2766397T1 (sl) | 2011-10-11 | 2018-09-28 | F. Hoffmann-La Roche Ag | Izboljšano sestavljanje bispecifičnih protiteles |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| PL2970422T3 (pl) | 2013-03-15 | 2018-09-28 | F.Hoffmann-La Roche Ag | Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania |
| JP2016520595A (ja) * | 2013-05-22 | 2016-07-14 | メタボリック エンジニアリング ラボラトリーズ カンパニー リミテッド | 抗ＴＮＦ−α／ＣＸＣＬ１０二重ターゲット抗体及びその用途 |
| US10370776B2 (en) * | 2013-09-25 | 2019-08-06 | Idea Orchard, Llc | Antibody like protein |
| LT3074424T (lt) | 2013-11-27 | 2025-05-26 | Zymeworks Bc Inc. | Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2 |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| PL3140392T3 (pl) * | 2014-05-06 | 2023-11-27 | F. Hoffmann-La Roche Ag | Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków |
| US10647777B2 (en) * | 2014-05-28 | 2020-05-12 | Genzyme Corporation | Methods of controlling the formation of disulfide bonds in protein solutions |
| CN104195173B (zh) * | 2014-09-02 | 2017-03-08 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
| RU2739500C2 (ru) | 2014-11-05 | 2020-12-25 | Дженентек, Инк. | Способы получения двуцепочечных белков в бактериях |
| CN108064308B (zh) * | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 细菌中产生双链蛋白的方法 |
| FI3223848T3 (fi) | 2014-11-27 | 2025-02-28 | Zymeworks Bc Inc | Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een |
| CN107922476A (zh) * | 2015-03-13 | 2018-04-17 | 诺夫免疫股份有限公司 | 纯化双特异性抗体的方法 |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| AU2016312259B2 (en) | 2015-08-26 | 2018-12-06 | Bison Therapeutics Inc. | Multispecific antibody platform and related methods |
| WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
| CA3026518A1 (en) | 2016-06-17 | 2017-12-21 | Genentech, Inc. | Purification of multispecific antibodies |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| US20190216925A1 (en) * | 2016-09-16 | 2019-07-18 | Leukocare Ag | A Novel Method for Stabilization of a Biopharmaceutical Drug Product During Processing |
| EP3512939B1 (en) | 2016-09-16 | 2026-06-17 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| JP7556687B2 (ja) * | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3615574B1 (en) | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| WO2018210898A1 (en) * | 2017-05-18 | 2018-11-22 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
| MA50102A (fr) | 2017-11-14 | 2020-07-15 | Univ Virginia Patent Foundation | Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques |
| JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| JP2021525806A (ja) | 2018-06-01 | 2021-09-27 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 疾患または状態を処置するための組成物およびそれらの使用 |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| US12435137B2 (en) | 2018-08-03 | 2025-10-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| JP2022501325A (ja) | 2018-09-28 | 2022-01-06 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子 |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| MA54070A (fr) | 2018-10-29 | 2021-09-08 | Biogen Ma Inc | Variants fc5 humanisés et stabilisés pour l'amélioration du transport à travers la barrière hémato-encéphalique |
| CN113260626B (zh) | 2018-11-05 | 2024-09-13 | 豪夫迈·罗氏有限公司 | 在原核宿主细胞中产生双链蛋白质的方法 |
| CN113795511B (zh) | 2019-01-23 | 2024-07-23 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| JP7812230B2 (ja) * | 2019-04-25 | 2026-02-09 | エフ． ホフマン－ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| EP3976649A4 (en) * | 2019-05-31 | 2022-12-14 | The Johns Hopkins University | B-SPECIFIC IL-6Ra/IL-8R BINDING AGENTS TO BLOCK MIGRATION OF CANCER CELLS |
| WO2020243479A1 (en) * | 2019-05-31 | 2020-12-03 | The Johns Hopkins University | Bispecific binding agents |
| AU2020350205A1 (en) | 2019-09-18 | 2022-05-12 | Lamkap Bio Alpha AG | Bispecific antibodies against CEACAM5 and CD3 |
| BR112022015140A2 (pt) | 2020-02-12 | 2022-10-11 | Janssen Biotech Inc | Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met |
| CN116096743A (zh) * | 2020-03-22 | 2023-05-09 | 科德路赛普特生物有限公司 | 用于病毒株进化的多聚体 |
| CA3173587A1 (en) | 2020-03-31 | 2021-10-07 | Chugai Seiyaku Kabushiki-Kaisha | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
| JP7736688B2 (ja) * | 2020-03-31 | 2025-09-09 | 中外製薬株式会社 | 多重特異性抗原結合分子を製造するための方法 |
| CN111748527B (zh) * | 2020-05-15 | 2021-01-29 | 上海多宁生物科技有限公司 | 化学成分限定高效补料培养基及其制备方法和应用 |
| WO2022082217A1 (en) | 2020-10-16 | 2022-04-21 | Eureka Therapeutics, Inc. | Compositions for preventing or treating viral and other microbial infections |
| CN114539417A (zh) * | 2020-11-26 | 2022-05-27 | 盛禾(中国)生物制药有限公司 | 一种有效去除双特异性抗体同源二聚体的层析纯化工艺 |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| CA3256035A1 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS |
| EP4508077A4 (en) | 2022-04-14 | 2026-03-25 | Invisishield Tech Ltd | COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS |
| WO2025088516A1 (en) * | 2023-10-26 | 2025-05-01 | Pfizer Inc. | Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained |
| TW202613165A (zh) | 2024-05-17 | 2026-04-01 | 比利時商Ｕｃｂ生物製藥公司 | 具有il-11和il-17結合特異性的多特異性抗體 |
| WO2026067827A1 (zh) * | 2024-09-30 | 2026-04-02 | 江苏恒瑞医药股份有限公司 | 一种制备异源多聚体的方法及应用 |
| US20260109746A1 (en) | 2024-10-22 | 2026-04-23 | Gilead Sciences, Inc. | Cd4-targeted il-15 molecules and methods of use |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| SE8505922D0 (sv) | 1985-12-13 | 1985-12-13 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| JP2665353B2 (ja) * | 1988-09-10 | 1997-10-22 | 住商ファーマインターナショナル株式会社 | 双特異性抗体の製造法 |
| WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| WO1996010400A1 (en) | 1994-09-30 | 1996-04-11 | The Uab Research Foundation | Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| HU229910B1 (hu) | 2001-05-11 | 2014-12-29 | Amgen Inc Thousand Oaks | A TALL-1-hez kötõdõ peptidek és rokon molekulák |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US6731168B2 (en) * | 2002-02-06 | 2004-05-04 | Intersil Americas, Inc. | Power amplifier linearizer that compensates for long-time-constant memory effects and method therefor |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CN1268761C (zh) * | 2002-08-29 | 2006-08-09 | 上海凯曼生物科技有限公司 | 一种制备人载脂蛋白基因重组蛋白的方法 |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| NZ540895A (en) | 2003-01-09 | 2007-03-30 | Genentech Inc | Purification of polypeptides with ethacridine lactate |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| NZ553118A (en) | 2004-09-02 | 2009-12-24 | Genentech Inc | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| WO2006028936A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070274985A1 (en) * | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| WO2007147901A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US8557446B2 (en) | 2006-08-14 | 2013-10-15 | Enerize Corporation | Proton-conducting polyamide polymer membrane and method for production |
| TW200821026A (en) | 2006-09-08 | 2008-05-16 | Wyeth Corp | Arginine wash in protein purification using affinity chromatography |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| DE102008048942B4 (de) | 2008-09-25 | 2011-01-13 | Siemens Aktiengesellschaft | Anordnung mit einer Wellendichtung |
| US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102712696A (zh) * | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| US20120259099A1 (en) | 2009-12-15 | 2012-10-11 | MuHyeon CHOE | Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers |
| BR112012014937B1 (pt) | 2009-12-18 | 2021-01-19 | Novartis Ag | método de produção de um anticorpo, fragmento de anticorpo ou proteína de fusão fc purificada usando uma matriz de cromatografia de afinidade |
| PT2560993T (pt) * | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| JP2013524816A (ja) | 2010-04-22 | 2013-06-20 | セネスコ テクノロジーズ，インコーポレイティド | 油の発現が増強された遺伝子導入藻類 |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| SI2766397T1 (sl) | 2011-10-11 | 2018-09-28 | F. Hoffmann-La Roche Ag | Izboljšano sestavljanje bispecifičnih protiteles |
-
2012
- 2012-10-11 SI SI201231347T patent/SI2766397T1/sl unknown
- 2012-10-11 CN CN201280060881.5A patent/CN104093744A/zh active Pending
- 2012-10-11 KR KR1020217004673A patent/KR102492792B1/ko active Active
- 2012-10-11 EP EP18167907.7A patent/EP3418306B1/en active Active
- 2012-10-11 HR HRP20240230TT patent/HRP20240230T1/hr unknown
- 2012-10-11 ES ES12778018.7T patent/ES2682081T3/es active Active
- 2012-10-11 PL PL18167907.7T patent/PL3418306T3/pl unknown
- 2012-10-11 HR HRP20181189TT patent/HRP20181189T1/hr unknown
- 2012-10-11 JP JP2014535885A patent/JP6216321B2/ja active Active
- 2012-10-11 HU HUE18167907A patent/HUE065876T2/hu unknown
- 2012-10-11 KR KR1020147012233A patent/KR102106002B1/ko active Active
- 2012-10-11 RU RU2014118743A patent/RU2654567C2/ru active
- 2012-10-11 KR KR1020207011816A patent/KR102219217B1/ko active Active
- 2012-10-11 HK HK15103323.5A patent/HK1202878A1/xx unknown
- 2012-10-11 WO PCT/US2012/059810 patent/WO2013055958A1/en not_active Ceased
- 2012-10-11 MX MX2014004322A patent/MX359384B/es active IP Right Grant
- 2012-10-11 BR BR112014008684-2A patent/BR112014008684B1/pt active IP Right Grant
- 2012-10-11 TR TR2018/09151T patent/TR201809151T4/tr unknown
- 2012-10-11 EP EP12778018.7A patent/EP2766397B1/en active Active
- 2012-10-11 PL PL12778018T patent/PL2766397T3/pl unknown
- 2012-10-11 CA CA2850818A patent/CA2850818A1/en active Pending
- 2012-10-11 CN CN201710312266.3A patent/CN107266577B/zh active Active
- 2012-10-11 ES ES18167907T patent/ES2971444T3/es active Active
-
2014
- 2014-04-11 US US14/251,428 patent/US9862778B2/en active Active
-
2017
- 2017-10-20 US US15/789,775 patent/US10626189B2/en active Active
-
2020
- 2020-03-16 US US16/820,660 patent/US11725065B2/en active Active
-
2023
- 2023-06-15 US US18/210,604 patent/US20240101714A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065861T3 (en) | Interleukin-31 monoclonal antibody | |
| SI2766397T1 (sl) | Izboljšano sestavljanje bispecifičnih protiteles | |
| IL272035A (en) | Anti IL–36R antibodies | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| IL234102B (en) | Bispecific igg4 antibodies are aligned symmetrically to the sequence | |
| SI2794658T1 (sl) | Bispecifična molekula protitelesa | |
| IL230772A0 (en) | Specific antibodies with subsequent fc | |
| PT2768857T (pt) | Métodos para purificar anticorpos | |
| ZA201407272B (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| GB201121564D0 (en) | Use of antibody | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| EP2714713A4 (en) | PURIFICATION OF ANTIBODIES | |
| HK1200844B (en) | Improved assembly of bispecific antibodies | |
| GB201108347D0 (en) | Polymprphic form of compound | |
| GB201105022D0 (en) | Methods |